Epidemiology, comorbidity, and use of systemic therapies in patients with paediatric psoriasis in Germany

被引:0
|
作者
Biermann, Mona [1 ,2 ]
Kolb, Benjamin [1 ]
机构
[1] Novartis Pharm GmbH, Nurnberg, Germany
[2] Novartis Pharma GmbH, Roonstr 25, D-90429 Nurnberg, Germany
关键词
Paediatric psoriasis; Systemic therapy; Comorbidity; Germany; CHILDHOOD PSORIASIS; CHILDREN; ADOLESCENTS; SAFETY; ETANERCEPT; PREVALENCE; EFFICACY; DISEASES;
D O I
10.1016/j.zefq.2023.10.004
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Introduction: Psoriasis is a chronic, inflammatory disorder with a physical and psychosocial burden. Recent epidemiological data on paediatric psoriasis in Germany is lacking. The aim of this study was to examine the prevalence, the incidence and associated epidemiological features of paediatric psoriasis in Germany using health claims data from a national health claims database.Methods: Continuously insured patients with paediatric psoriasis (2014-2017) from the Institute of Applied Health Research Berlin (InGef) database were included in this analysis. Between 2014 and 2017, we analysed the prevalence and incidence of paediatric psoriasis (aged < 17 years), relevant comorbidities, the most frequently attended and diagnosing medical specialties, and the number of systemic treatment prescriptions.Results: Overall, psoriasis prevalence (0.15-0.16%) and incidence (0.06-0.07%) remained stable between 2014 and 2017; both prevalence and incidence were higher in female patients. Psoriasis prevalence gradually increased with age between the age groups <6 years and 16-17 years. Obesity (11.5%) and somato-form disorders (7.0%) were the most common comorbidities identified. Overall, 90.4% of the psoriasis cases were diagnosed by either a dermatologist (50.9%), general practitioner (27.8%), or paediatrician (11.7%). Patients most frequently attended general practitioners (74.5%), dermatologists (57.9%) and paediatricians (56.5%). The use of systemic treatment(s) increased from 4.7% to 5.4% between 2014 and 2017.Discussion: The prevalence and incidence of paediatric psoriasis in Germany remained stable between 2014 and 2017, with a higher prevalence and incidence observed in females and older adolescents. Obesity and somatoform disorders were the most common comorbidities. General practitioners, dermatologists, and paediatricians were most often involved in the treatment of patients, highlighting the need for interdisciplinary management of paediatric psoriasis.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 50 条
  • [21] Update on systemic therapies in paediatric dermatology
    Mohme, Sophia
    Alband, Neda
    Diaz, Angel Rosell
    Lefevre, Marine-Alexia
    Rodriguez-Lomba, Enrique
    Nogueira, Miguel
    Goebeler, Matthias
    Hamm, Henning
    EUROPEAN JOURNAL OF DERMATOLOGY, 2021, 31 (05) : 672 - 675
  • [22] Update on systemic therapies in paediatric dermatology
    Sophia Mohme
    Neda Alband
    Angel Rosell Diaz
    Marine-Alexia Lefevre
    Enrique Rodriguez-Lomba
    Miguel Nogueira
    Matthias Goebeler
    Henning Hamm
    European Journal of Dermatology, 2021, 31 : 672 - 675
  • [23] Novel systemic therapies for the treatment of psoriasis
    Tan, Ki-Wei
    Griffiths, Christopher E. M.
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (01) : 79 - 92
  • [24] PATHOMECHANISMS AND NEW SYSTEMIC THERAPIES IN PSORIASIS
    WEBER, G
    ACTA DERMATO-VENEREOLOGICA, 1984, : 147 - 149
  • [25] Epidemiology and Treatment of Patients with Psoriasis (PSO) or Psoriatic Arthritis (PsA) in Germany
    Dombrowsky, W.
    Fabricius, V
    Grellmann, C.
    Suruki, R.
    Sheahan, A.
    Joeres, L.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 102 - 103
  • [26] Consistent response with infliximab in psoriasis patients independent of previous systemic therapies
    Phillip, S.
    Thaci, D.
    Brau, B.
    Sterry, W.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 : S26 - S26
  • [27] Clinical pharmacokinetics and pharmacodynamics of oral systemic nonbiologic therapies for psoriasis patients
    Eichinger, Justin M.
    Shan, Divya M.
    Greenzaid, Jonathan D.
    Anakwenze, Lisa
    Feldman, Steven R.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2024, 20 (04) : 249 - 262
  • [28] Epidemiology of mental health comorbidity in patients with psoriasis: An analysis of trends from 1986 to 2019
    Liu, Liu
    Lin, Nai-xuan
    Yu, Yuan-ting
    Wang, Si-han
    Wang, Jiao
    Cai, Xiao-ce
    Wang, Chun-xiao
    Zhang, Miao
    Li, Xin
    Li, Bin
    PSYCHIATRY RESEARCH, 2023, 321
  • [29] Systemic therapies for psoriasis: Understanding current and newly emerging therapies
    Sobell, JM
    Hallas, SJ
    SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2003, 22 (03) : 187 - 195
  • [30] Treat paediatric psoriasis with traditional and novel topical therapies
    Brown, Michael B.
    Kang, Connie
    DRUGS & THERAPY PERSPECTIVES, 2024, 40 (12) : 466 - 469